Publication Cover
Expert Review of Precision Medicine and Drug Development
Personalized medicine in drug development and clinical practice
Volume 1, 2016 - Issue 2
13,335
Views
5
CrossRef citations to date
0
Altmetric
Review

Precise treatment of cystic fibrosis – current treatments and perspectives for using CRISPR

, &
Pages 169-180 | Received 24 Nov 2015, Accepted 20 Jan 2016, Published online: 16 Feb 2016

Figures & data

Figure 1. Mechanism of CFTR channel gating. The CFTR channel consists of two membrane spanning domains (MSD), two nucleotide binding domains (NBD) and a single regulatory domain (RD). Following the phosphorylation of the RD by protein kinase A (PKA) and the hydrolysis of an ATP on the NBD, the CFTR channel gate moves to an open conformation and allows the passage of chloride (Cl) ions (adapted from reference 6, Chen et al, 2006 with kind permission from S. Karger AG, Basel).

Figure 1. Mechanism of CFTR channel gating. The CFTR channel consists of two membrane spanning domains (MSD), two nucleotide binding domains (NBD) and a single regulatory domain (RD). Following the phosphorylation of the RD by protein kinase A (PKA) and the hydrolysis of an ATP on the NBD, the CFTR channel gate moves to an open conformation and allows the passage of chloride (Cl−) ions (adapted from reference 6, Chen et al, 2006 with kind permission from S. Karger AG, Basel).

Figure 2. A schematic representation of class I to class VI mutations in cystic fibrosis. Class I mutations lead to a complete lack of production of the CFTR protein. Class II mutations result in defective handling of CFTR, typically stimulating ER retention and degradation. Class III and class IV mutations disrupt CFTR function by decreasing its gating ability and conductance respectively. Defective splicing of pre-mRNA to mRNA typically underlies class V mutations. Finally, class VI mutations increase the turn-over of CFTR at the cell membrane.

Figure 2. A schematic representation of class I to class VI mutations in cystic fibrosis. Class I mutations lead to a complete lack of production of the CFTR protein. Class II mutations result in defective handling of CFTR, typically stimulating ER retention and degradation. Class III and class IV mutations disrupt CFTR function by decreasing its gating ability and conductance respectively. Defective splicing of pre-mRNA to mRNA typically underlies class V mutations. Finally, class VI mutations increase the turn-over of CFTR at the cell membrane.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.